Efficacy News and Research

RSS

AI-powered analytics and experimental validation: Transforming target identification in drug discovery

Discover how AI-powered analytics and experimental validation combine to improve target identification and accelerate drug discovery success.

From Axxam S.p.A 23 Jul 2026

Short-term immunosuppressive therapy briefly restores autism-like brain changes in adult mice

A new mouse study led by UCLA Health suggests that inflammation during pregnancy can trigger autism-like changes in offspring, but also that those brain and behavior effects may be rapidly but temporarily reversible in adulthood with a short-term dose of the immunosuppressive drug rapamycin.

23 Jul 2026

Ancient immune protein C3 boosts cancer immunotherapy within tumors

An ancient molecule that existed long before the blood circulation system evolved, has been found to support cancer immunotherapy.

23 Jul 2026

Spermidine boosts key cellular processes linked to aging in early research

This review finds that spermidine supports autophagy, mitochondrial function, and healthspan in experimental models, while observational studies link higher dietary intake to lower mortality. However, human trials have produced limited and mixed results, leaving its clinical role in healthy aging unresolved.

23 Jul 2026

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

AI platform uncovers promising target for chronic pain treatmen

Despite the widespread availability of analgesics, pain management remains one of the most significant and pervasive challenges in modern medicine, with more than 20% of the global population suffering from chronic pain, especially chronic neuropathic pain characterized by central sensitization.

22 Jul 2026

Experimental neurointerventional technique shows promise for severe back pain

Researchers at the Society of NeuroInterventional Surgery (SNIS) 23rd Annual Meeting presented an experimental neurointerventional technique designed to treat severe back pain, a leading cause of disability and opioid use, by delivering medication directly through the arteries supplying the painful area.

22 Jul 2026

Study reveals how p53 mutations cause tumors to resist cancer immunotherapy

Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant.

22 Jul 2026

Swimming can be clinically effective in reducing disability from chronic low back pain

Australian research has shown for the first time that a program of swimming can be clinically effective in reducing disability from chronic low back pain.

21 Jul 2026

Tailored gene therapy dramatically reduces childhood epilepsy seizures in trial

SCN2A‑related developmental epileptic encephalopathy (DEE) is a rare, severe form of childhood epilepsy and one of the most common causes of monogenic autism.

21 Jul 2026

Oral drug avatrombopag reduces chemotherapy treatment delays, trial finds

In a phase 2 trial of patients with gastrointestinal cancers, avatrombopag helped 70% of those receiving chemotherapy to stay on treatment schedule, compared with 17% receiving placebo.

20 Jul 2026

Study explores membrane repair mechanisms in leishmaniasis parasites

Texas Tech University faculty Peter Keyel and Kai Zhang are teaming up to build foundational knowledge concerning leishmaniasis, a common, but neglected protozoan parasitic disease.

20 Jul 2026

Semaglutide vs. liraglutide: Head-to-head study reveals a diabetes risk difference

Researchers compared semaglutide with liraglutide in 57,456 insured adults without recorded diabetes or cardiovascular disease who initiated formulations indicated for chronic weight management. Semaglutide users had a lower risk of incident diabetes, particularly beyond six months of follow-up, but limited cardiovascular events prevented a precise comparison of cardiovascular risk.

20 Jul 2026

Gut microbial metabolites may shape vulnerability to stress-related mental disorders

Gut microbiome-derived metabolites may influence stress-related mental disorders through neural, immune, endocrine, and epigenetic pathways. Evidence is strongest for depression and preclinical models, while larger longitudinal human studies are needed to establish causality and clinical value.

20 Jul 2026